Repligen (RGEN) Misses Q2 EPS by 2c; offers guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $176.27 -3.16%
Financial Fact:
(Loss) income from operations: 3.75M
Today's EPS Names:
CHA, EDXC, YAYO, More
Financial Fact:
(Loss) income from operations: 3.75M
Today's EPS Names:
CHA, EDXC, YAYO, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.37, $0.02 worse than the analyst estimate of $0.39. Revenue for the quarter came in at $182 million versus the consensus estimate of $175.35 million.
GUIDANCE:
Repligen sees FY2025 EPS of $1.65-$1.72, versus the consensus of $1.68. Repligen sees FY2025 revenue of $715-735 million, versus the consensus of $710.2 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Electra Therapeutics files for proposed IPO
- Goldman Sachs Starts GenFleet Therapeutics Shanghai (2595:HK) at Buy
- Jiayin Group (JFIN) Reports Q2 Loss of RMB3.56
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
